Sanofi is conducting a Phase 3 study titled A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study, Followed by Open-label Extensions, to Evaluate the Efficacy of Oral ...

Sanofi has announced a new clinical study titled ‘A Multi-center, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) ...

Paris: Sanofi has announced that the European Medicines Agency has granted orphan designation to rilzabrutinib, a reversible ...

Sanofi's Chief Digital Officer Emmanuel Frenehard had a thought that he just couldn't shake: how can Sanofi extend the lifespan for patients around the world? To solve the problem, Frenehard ...

The cost-effectiveness of the drug for NHS roll-out will now be assessed by the National Institute for Health and Care ...

Mumbai: Sanofi India has announced the appointment of Richa Bakshi as the People Excellence Lead (Senior Management Personnel ...

In addition to IgG4-related disease, rilzabrutinib has received orphan designations for immune thrombocytopenia (ITP) in the US, the EU, and Japan; and for warm autoimmune hemolytic anemia, IgG4-RD ...

Response Pharmaceuticals’ drug has helped reduce the amount of weight a patient regains after treatment with glucagon-like ...

Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in ...

Sanofi (SNY) halts shipments of cholesterol drug Praluent developed with Regeneron (REGN) due to availability issues. Read ...

A company that has Donald Trump Jr. on its board debuted a new service to help pharmaceutical companies launch direct sales ...

Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French ...